The stock of Endocyte, Inc. (NASDAQ:ECYT) is a huge mover today! About 145,897 shares traded hands. Endocyte, Inc. (NASDAQ:ECYT) has declined 0.31% since March 2, 2016 and is downtrending. It has underperformed by 8.56% the S&P500.
The move comes after 6 months positive chart setup for the $151.69M company. It was reported on Oct, 5 by Barchart.com. We have $8.45 PT which if reached, will make NASDAQ:ECYT worth $215.40M more.
Analysts await Endocyte, Inc. (NASDAQ:ECYT) to report earnings on November, 1. They expect $-0.29 earnings per share, down 20.83% or $0.05 from last year’s $-0.24 per share. After $-0.25 actual earnings per share reported by Endocyte, Inc. for the previous quarter, Wall Street now forecasts 16.00% negative EPS growth.
Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage
Out of 2 analysts covering Endocyte (NASDAQ:ECYT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Endocyte has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Wednesday, August 5 by RBC Capital Markets. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. The stock of Endocyte, Inc. (NASDAQ:ECYT) has “Outperform” rating given on Wednesday, November 4 by RBC Capital Markets.
According to Zacks Investment Research, “Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based in West Lafayette, Indiana.”
Insitutional Activity: The institutional sentiment decreased to 0.87 in Q2 2016. Its down 0.25, from 1.12 in 2016Q1. The ratio worsened, as 10 funds sold all Endocyte, Inc. shares owned while 29 reduced positions. 9 funds bought stakes while 25 increased positions. They now own 15.26 million shares or 5.31% less from 16.12 million shares in 2016Q1.
Dimensional Fund Advsr Lp last reported 0% of its portfolio in the stock. Spark Ltd Liability holds 0.04% or 116,900 shares in its portfolio. Stoneridge Investment Ltd Limited Liability Company accumulated 0.02% or 41,199 shares. Yakira Capital Management Inc holds 14,200 shares or 0.02% of its portfolio. Bessemer Group Inc Inc reported 15,850 shares or 0% of all its holdings. Legal General Public Ltd Co owns 6,833 shares or 0% of their US portfolio. Deutsche Retail Bank Ag last reported 0% of its portfolio in the stock. Tower Llc (Trc) accumulated 4,466 shares or 0% of the stock. Camarda Finance Advisors Lc holds 1,000 shares or 0% of its portfolio. Gemmer Asset Mgmt Limited Liability Co accumulated 1,500 shares or 0% of the stock. Blackrock Management Limited Liability Co reported 159,905 shares or 0% of all its holdings. Blackrock Institutional Tru Na holds 0% or 518,217 shares in its portfolio. Manufacturers Life Insur The holds 0% or 1,496 shares in its portfolio. Cornerstone Advsr Inc holds 250 shares or 0% of its portfolio. Jpmorgan Chase & Company last reported 782,485 shares in the company.
Insider Transactions: Since May 10, 2016, the stock had 1 buy, and 0 sales for $40,040 net activity. Low Philip S bought 11,375 shares worth $40,040.
More notable recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Fool.com which released: “Why Endocyte Inc. Shares Plummeted in After Hours” on June 18, 2014, also Ibj.com with their article: “CEO Ellis resigns after 20 years at struggling drug firm Endocyte” published on June 21, 2016, Quotes.Wsj.com published: “Endocyte Inc. ECYT (US: Nasdaq)” on August 20, 2010. More interesting news about Endocyte, Inc. (NASDAQ:ECYT) were released by: Fool.com and their article: “Why Endocyte, Inc. Stock Briefly Spiked Higher” published on September 29, 2014 as well as Globenewswire.com‘s news article titled: “Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference” with publication date: August 09, 2016.
ECYT Company Profile
Endocyte Inc. (Endocyte), incorporated on December 11, 2001, is a biopharmaceutical company. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), PSMA Tubulysin (EC1169), Vintafolide (Folate DAVLBH), Folate-DNA alkylator (EC1788), Folate-Aminopterin (EC1669), Folate-mTor inhibitor (EC0371), Etarfolatide (Folcepri or Tc99m) and PSMA- Tc99m (EC0652).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.